Alkem Labs Q2 Net Profit Soars 77% to Rs. 615 Crore

The 11,600 crore pharma giant has reported a significant increase in net profit for the second quarter ending in September 2023, driven by strong international sales. The company's net profit has increased by 77 percent to Rs. 615 crore rupees an exceptional item of Rs. The account recorded a debit of 58 crore due to the impairment of fixed assets. The revenue of the company rose by 11.8 percent to Rs. 3,448 crore from 3,448,00,00,00,000 Rs. Three thousand and seventy-nine crore. The EPS is Rs. The face value of the share has been increased to Rs. The value of 27.67 was recorded in the previous period. Alkem's domestic sales saw a modest 5 per cent increase, reaching Rs. The revenue in the second quarter increased to Rs. 2,328 crore from Rs. 2.216 billion rupees during the same period last year.

The sporadic rainfall had a negative impact on sales, causing pressure on the growth of the anti-infective sector. Despite this, the market for anti-diabetic drugs continues to grow. International sales surged by 27.1 percent to Rs. 1,054 crore rupees. The amount is 829 crore. US sales increased by 27.1 percent to Rs. from this. The amount collected is Rs. 768 crore. The international markets, including 604 crore, contributed to Rs. "287 crore" In the September quarter, sales from other international markets accounted for 8.5 percent of the total sales. Alkem operates primarily in Latin America, Australia, Europe, South East Asia, Africa, and CIS. During the quarter being reviewed, all of its major markets including Chile, UK, Kazak, and the Philippines have experienced significant growth.